Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

For Struggling Single Moms, 3-Generation Households Are Better Than 2
Living in a three-generation household can significantly enhance the economic well-being of children, according to a new study from researchers at the University of Southern California and the University of Massachusetts, Boston.
generic viagra online
Abbott Initiates Trial Of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes From SPIRIT Family Of Trials
Abbott (NYSE: ABT) announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company"s next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States. The first patient was enrolled into the SPIRIT PRIME clinical trial at Hillcrest Medical Center in Tulsa, Okla., by Rajesh Chandwaney, M.D.
News of the day
Health Care Experts Examine Top Performing, Low Cost Communities
Talk about health care reform efforts has focused largely on all that is wrong with the current system. In contrast, an event Tuesday in Washington, D.C., examined best practices in ten top performing communities where they spend less and have better quality of care.
Nutrition

Association For Molecular Pathology Comments To The SACGHS

In public comments given before the Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society (SACGHS), the Association for Molecular Pathology (AMP) addressed three areas: Comparative Effectiveness Research (CER), evidence for coverage of genetic and genomic tests, and gene patents. AMP first summarized the organization"s recent extensive comment letter to the Federal Coordinating Council on Comparative Effectiveness Research: * AMP encourages the development of a comprehensive infrastructure for CER and laboratory tests, which should include a panel of expert stakeholders with molecular diagnostics experience. * AMP urges that funding for large, carefully designed comparative effectiveness trials for molecular tests be coupled with funding for comparative effectiveness studies that complement randomized controlled trials by including patients who do not necessarily meet the inclusion criteria for prospective trials. * AMP calls for funding to develop new reference materials and innovative testing methods to advance laboratory quality measures. AMP next addressed the closely related issue of reimbursement, summarizing the organization"s comments to the CMS MEDCAC. AMP maintains that the evidence required for coverage of most genetic and genomic tests should not differ from the requirements for other diagnostic tests. Last, AMP referred to their extensive comments to the SACGHS draft report on gene patents and licensing practices. AMP believes that while the Draft Report raises many key questions, it misses an opportunity to more definitively explore the negative impact on public health that derives from exclusive and restrictive licensing practices, such as with the case of the genes associated with SMA and the Connexin-26, and Connexin-30 genes. AMP encouraged the Secretary"s Advisory Committee to consider additional case studies that demonstrate this point. A copy of AMP"s comments to the SACGHS as well as the full comments to the Federal Coordinating Council and MEDCAC can be found here. Mary Steele Williams Association for Molecular Pathology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009